Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes
Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N
Published in Current Medical Research and Opinion
Methodology
Randomised, double-blind, placebo-controlled trial of prolonged-release melatonin 2 mg for three weeks in patients aged 55-80 with primary insomnia, with a run-in and withdrawal period.
Key Findings
Prolonged-release melatonin significantly improved sleep quality and morning alertness versus placebo, with shortened sleep latency and no rebound insomnia or withdrawal effects on discontinuation.
Conclusions
Prolonged-release melatonin improves sleep quality and next-day functioning in older adults with insomnia.
Limitations
Short duration; manufacturer-sponsored; benefits concentrated in older adults with low endogenous melatonin.
Supplements Studied
Prolonged-release melatonin significantly improved sleep quality and morning alertness versus placebo, with no rebound insomnia.
Outcomes Measured
Prolonged-release melatonin improved sleep quality and next-day alertness in older adults.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Neurim Pharmaceuticals (manufacturer)
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.